Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.63 |
| ▸ | DDB1 | Q16531 | 15/20 | 0.63 |
| ▸ | IKZF3 | Q9UKT9 | 4/20 | 0.63 |
| ▸ | PRPS1 | P60891 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23065972 | 0.82 | CRBN (0.73) | CRBNDDB1IKZF3 | |
| SCHEMBL25654122 | 0.82 | CRBN (0.73) | CRBNDDB1IKZF3TNF | |
| SCHEMBL23066007 | 0.81 | CRBN (0.65) | CRBNDDB1IKZF3 | |
| SCHEMBL22511857 | 0.80 | CRBN (0.73) | CRBNDDB1IKZF3 | |
| SCHEMBL25653899 | 0.80 | CRBN (0.73) | CRBNDDB1IKZF3TNF | |
| SCHEMBL23066096 | 0.80 | CRBN (0.47) | CRBNDDB1IKZF3TNF | |
| SCHEMBL23066127 | 0.80 | CRBN (0.55) | CRBNDDB1IKZF3TNF | |
| SCHEMBL31612891 | 0.78 | CRBN (0.57) | CRBNDDB1IKZF3TNF | |
| SCHEMBL25653922 | 0.78 | CRBN (0.56) | CRBNDDB1IKZF3 | |
| SCHEMBL19586751 | 0.78 | CRBN (1.00) | CRBNDDB1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159559-A1 | COMPOUND FOR INHIBITING AND INDUCING DEGRADATION OF EGFR KINASE | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159559-A1 | COMPOUND FOR INHIBITING AND INDUCING DEGRADATION OF EGFR KINASE | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| EP-4019021-A1 | COMPOUND INHIBITING AND INDUCING DEGRADATION OF EGFR AND ALK | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021121261-A1 | COMPOUND FOR INHIBITING AND INDUCING DEGRADATION OF EGFR KINASE | 北京泰德制药股份有限公司 | 2021-06-24 | — | — | WO | disclosed |
| WO-2021036922-A1 | COMPOUND INHIBITING AND INDUCING DEGRADATION OF EGFR AND ALK | 北京泰德制药股份有限公司 | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159559-A1 | COMPOUND FOR INHIBITING AND INDUCING DEGRADATION OF EGFR KINASE | EGFR, ERBB2, ERBB3 | CRBN 898/4885DDB1 2765/4885IKZF3 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.